First-line cytoreductive treatment in MNPs

Chris Hillis

Dr Chris Hillis is an assistant professor in the Division of Oncology at McMaster University and hematologist at the Juravinski Hospital and Cancer Centre.

Which cytoreductive drug is your first-line option for the treatment of myeloproliferative neoplasms (MNPs)?

Chris Hillis, MD, MSc: Hydroxyurea or hydroxycarbamide remain the first-line cytoreductive therapies in MPNs in 2019. In young patients and in patients who wish to become pregnant who do require cytoreductive therapy we would use interferon as first-line [treatment].

See also

We would love to hear from you

Comments, mistakes, suggestions?

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.